A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Latest Information Update: 24 Nov 2021
At a glance
- Drugs Reproxalap (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors Aldeyra Therapeutics
- 01 May 2018 According to an Aldeyra Therapeutics media release, data from this trial was presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- 21 Feb 2018 According to an Aldeyra Therapeutics media release, data will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.